-IDEAYA Biosciences Announces Phase 1/2 Clinical Trial Progress for IDE196 to be Presented at Society for Melanoma Research Congress

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced that it will present data from an ongoing Phase 1/2 clinical trial entitled "A Phase 1/2 Study in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions" (ClinicalTrials.gov Identifier: NCT03947

Benzinga · 11/15/2019 11:02